Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Express Scripts
Boehringer Ingelheim
Moodys
AstraZeneca

Last Updated: July 4, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for AUY922


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug AUY922?

AUY922 is an investigational drug.

There have been 25 clinical trials for AUY922. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2010.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).

There are nine US patents protecting this investigational drug and fifty-nine international patents.

Recent Clinical Trials for AUY922
TitleSponsorPhase
A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung CancerNovartis PharmaceuticalsPhase 2
Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung CancerNational Cancer Institute (NCI)Phase 1
Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung CancerJonsson Comprehensive Cancer CenterPhase 1

See all AUY922 clinical trials

Clinical Trial Summary for AUY922

Top disease conditions for AUY922
Top clinical trial sponsors for AUY922

See all AUY922 clinical trials

US Patents for AUY922

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AUY922   Start Trial Remote loading of sparingly water-soluble drugs into lipid vesicles ZONEONE PHARMA, INC. (San Francisco, CA)   Start Trial
AUY922   Start Trial Azabicyclo derivatives, process for preparation thereof and medical use thereof Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (Shanghai, CN) Yangtze River Pharmaceutical Group Co., Ltd. (Jiangsu, CN)   Start Trial
AUY922   Start Trial Resistant mutant 90 kDa heat shock protein Taiho Pharmaceutical Co., Ltd. (Tokyo, JP)   Start Trial
AUY922   Start Trial Molecular diagnostic test for cancer Almac Diagnostic Services Limited (Craigavon, GB)   Start Trial
AUY922   Start Trial HER2 polypeptides useful for imaging and monitoring tumors and cancers IMPERIAL INNOVATIONS LIMITED (London, GB) GE HEALTHCARE LIMITED (Buckinghamshire, GB)   Start Trial
AUY922   Start Trial Biomarkers of tumor pharmacodynamic response Novartis AG (Basel, CH)   Start Trial
AUY922   Start Trial Molecular diagnostic test for cancer ALMAC DIAGNOSTICS LIMITED (GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AUY922

Drugname Country Document Number Estimated Expiration Related US Patent
AUY922 Australia 2015301234 2034-08-04   Start Trial
AUY922 Canada 2962709 2034-08-04   Start Trial
AUY922 China 106999419 2034-08-04   Start Trial
AUY922 European Patent Office 3177269 2034-08-04   Start Trial
AUY922 World Intellectual Property Organization (WIPO) 2016022549 2034-08-04   Start Trial
AUY922 China 105524068 2034-09-30   Start Trial
AUY922 European Patent Office 3202767 2034-09-30   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Colorcon
Johnson and Johnson
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.